Marubi's HK IPO Application Lapses, Ranks 3rd in China's Recombinant Collagen Skincare Segment

NewTimeSpace News: As shown on the official website of the Hong Kong Stock Exchange, the Main Board listing application filed by Guangdong Marubi Biotechnology Co., Ltd. on December 11, 2025 has lapsed after six months. Goldman Sachs and CITIC Securities served as joint sponsors for the application.
Marubi Biotechnology is a leading Chinese beauty enterprise dedicated to providing anti-aging solutions, with more than two decades of experience in the anti-aging skincare industry. According to Frost & Sullivan reports, the company is the third largest beauty player in China's recombinant collagen skincare segment by retail sales in 2024. It has independently developed recombinant dual collagen. The company is a major drafter of the industry standard Recombinant Soluble Collagen approved by the Ministry of Industry and Information Technology, and also the first enterprise in China accredited as the National Research Center for Recombinant Functional Protein Technology.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.